阿米三嗪输注在SARS-CoV-2诱导的急性呼吸窘迫综合征中的应用:单中心观察性研究
阿米三嗪以10 μg/kg/min每小时静脉给药,多数(75%)联合吸入一氧化氮。中位P/F改善39%(9-93%),应答者改善67%(39-131%)而非应答者仅6%(9-16%),差异显著(p<0.0001)。28天死亡率应答者47.6% vs 非应答者63.6%(p=0.39),血流动力学参数试验前后相似。结论认为阿米三嗪可改善氧合且无不良效应,可能作为多步骤管理重度低氧血症的治疗选项。
要点
- 适用人群为SARS-CoV-2确诊、符合柏林定义ARDS且P/F<150 mmHg的重度低氧血症患者,阿米三嗪作为推荐治疗之外的附加治疗。
- 给药方案为10 μg/kg/min每小时静脉输注,多数(75%)联合吸入一氧化氮;应答定义为输注结束时P/F较基线升高≥20%。
- 28天死亡率应答者47.6% vs 非应答者63.6%(p=0.39),无统计学差异;血流动力学参数试验前后相似,未提示急性肺心病。
适用人群与场景
- 纳入:经RT-PCR确诊SARS-CoV-2感染、符合柏林定义ARDS、P/F<150 mmHg的重度低氧血症患者,在推荐治疗基础上考虑阿米三嗪。
- 排除:原文未提及。
- 场景:法国里尔教学医院ICU,2020年2月27日至4月14日。
诊断标准与关键阈值
- ARDS诊断依据柏林定义。
- 阿米三嗪启用条件:Severe hypoxemia,Pao2/Fio2 ratio < 150 mm Hg。
- 应答标准:输注结束时Pao2/Fio2 ratio较基线升高≥20%。
处置流程与药物剂量
- 第一步:对SARS-CoV-2确诊、符合柏林定义ARDS且P/F<150 mmHg的重度低氧血症患者,在推荐治疗基础上考虑阿米三嗪输注试验。
- 第二步:阿米三嗪以10 μg/kg/min每小时静脉输注。
- 第三步:多数(75%)联合吸入一氧化氮。
- 第四步:输注前和输注结束后即刻行动脉血气比较,计算P/F变化,P/F升高≥20%定义为应答。
- 目标值:P/F较基线升高≥20%为阳性应答;原文未提及其他目标值或疗程。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 干预:阿米三嗪10 μg/kg/min每小时静脉输注,75%联合吸入一氧化氮;对照:输注前与输注结束后即刻血气比较。
- 应答者P/F改善67%(39-131%)vs 非应答者6%(9-16%),p<0.0001。
- 28天死亡率:应答者47.6% vs 非应答者63.6%(p=0.39)。
- 血流动力学参数试验前后相似,未提示急性肺心病。
证据类型、等级与局限
- 证据类型:单中心回顾性观察性研究。
- 证据等级或推荐强度:原文未提及。
- 局限:原文未述局限性。
对床旁实践的改变
- 对SARS-CoV-2相关重度ARDS(P/F<150 mmHg)患者,在推荐治疗基础上可考虑阿米三嗪10 μg/kg/min每小时静脉输注以改善氧合,66%患者有应答。
- 阿米三嗪对28天死亡率无显著影响(应答者47.6% vs 非应答者63.6%,p=0.39),不应以降低死亡率为目的使用。
指南或共识出处
- Almitrine Infusion in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Acute Respiratory Distress Syndrome: A Single-Center Observational Study. Crit Care Med.
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Treating acute respiratory failure in patients with coronavirus disease 2019 is challenging due to the lack of knowledge of the underlying pathophysiology. Hypoxemia may be explained in part by the loss of hypoxic pulmonary vasoconstriction. The present study assessed the effect of almitrine, a selective pulmonary vasoconstrictor, on arterial oxygenation in severe acute respiratory syndrome coronavirus 2-induced acute respiratory distress syndrome.
DESIGN: Single-center retrospective observational study.
SETTING: ICU of Lille Teaching Hospital, France, from February 27, 2020, to April 14, 2020.
PATIENTS: Patients with coronavirus disease 2019 pneumonia confirmed by positive reverse transcriptase-polymerase chain reaction for severe acute respiratory syndrome-coronavirus 2 and acute respiratory distress syndrome according to Berlin definition. Data focused on clinicobiological features, ventilator settings, therapeutics, outcomes, and almitrine-related adverse events.
INTERVENTIONS: Almitrine was considered in patients with severe hypoxemia (Pao2/Fio2 ratio < 150 mm Hg) in addition to the recommended therapies, at an hourly IV delivery of 10 μg/kg/min. Comparative blood gases were done before starting almitrine trial and immediately after the end of the infusion. A positive response to almitrine was defined by an increase of Pao2/Fio2 ratio greater than or equal to 20% at the end of the infusion.
MEASUREMENTS AND MAIN RESULTS: A total of 169 patients were enrolled. Thirty-two patients with acute respiratory distress syndrome received an almitrine infusion trial. In most cases, almitrine was infused in combination with inhaled nitric oxide (75%). Twenty-one patients (66%) were responders. The median Pao2/Fio2 ratio improvement was 39% (9-93%) and differs significantly between the responders and nonresponders (67% [39-131%] vs 6% [9-16%], respectively; p < 0.0001). The 28-day mortality rates were 47.6% and 63.6% (p = 0.39) for the responders and nonresponders, respectively. Hemodynamic parameters remained similar before and after the trial, not suggesting acute cor pulmonale.
CONCLUSIONS: Almitrine infusion improved oxygenation in severe acute respiratory syndrome coronavirus 2-induced acute respiratory distress syndrome without adverse effects. In a multistep clinical approach to manage severe hypoxemia in this population, almitrine could be an interesting therapeutic option to counteract the loss of hypoxic pulmonary vasoconstriction and redistribute blood flow away from shunting zones.
参考来源
- Caplan M, Goutay J, Bignon A, et al. Almitrine Infusion in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Acute Respiratory Distress Syndrome: A Single-Center Observational Study. Crit Care Med. 2021. PMID: 33093279. doi:10.1097/CCM.0000000000004711
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。